WHO seeks 'additional clarifications' from Bharat Biotech for Covaxin to conduct final 'risk-benefit assessment'

"The TAG met today (26 October 2021) and decided that additional clarifications from the manufacturer are needed to conduct a final EUL risk-benefit assessment for global use of the vaccine," the WHO said in an email response to a question by PTI on the decision regarding the Emergency Use Listing of Covaxin.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2ZlW6Kb
via IFTTT